Wir sind mit live! Mehr erfahren

Intelligent Bio Solutions

INBS

Börsenwert 4,98 Mio. $

1,50 USD

+0,06

4,17 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

1,52

+0,02

1,33 %

1 Tag

4,17 %

5 Tage

-2,6 %

1 Monat

-23,86 %

3 Monate

-31,82 %

6 Monate

-44,44 %

Seit Jahresbeginn

-80,99 %

1 Jahr

-85,44 %

5 Jahre

-99,97 %

10 Jahre

-99,99 %

Profil: Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.

Mitarbeiter: 60

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 8,3 %

Neutral 91,7 %

Negativ 0 %

Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript

Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript

Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript

Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET

Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S. Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.

Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA), seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System (the “System”) for detection of the opiate codeine.

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules

$5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System $5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit.

Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification

Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it pursues FDA clearance Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it pursues FDA clearance

Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification

Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Usability Study for the Intelligent Fingerprinting Drug Screening System, supporting its FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. The study was conducted in partnership with CenExel Clinical Research, Inc., following FDA guidance and ICH GCP (International Council for Harmonisation Good Clinical Practice) standards.

Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission

Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System. The study supports the Company's FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine.

Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt